Drug Profile
Research programme: necroptosis stimulants - TetraLogic Pharmaceuticals
Latest Information Update: 16 Jan 2014
Price :
$50
*
At a glance
- Originator TetraLogic Pharmaceuticals
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cardiovascular disorders; Eye disorders; Neurological disorders
Most Recent Events
- 16 Jan 2014 No development reported - Preclinical for Cardiovascular disorders in USA (unspecified route)
- 16 Jan 2014 No development reported - Preclinical for Eye disorders in USA (unspecified route)
- 16 Jan 2014 No development reported - Preclinical for Neurological disorders in USA (unspecified route)